Similar articles for PMID: 20660382

Year	Number of Results
1992	1
1998	1
1999	2
2000	1
2001	2
2002	3
2003	3
2004	3
2005	3
2006	1
2007	8
2008	4
2009	10
2010	15
2011	8
2012	13
2013	18
2014	15
2015	17
2016	24
2017	23
2018	18
2019	20
2020	15
2021	7
2022	10
2023	5
2024	0

1

18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.

De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. De Giorgi U, et al. J Nucl Med. 2010 Aug;51(8):1213-8. doi: 10.2967/jnumed.110.076455. Epub 2010 Jul 21. J Nucl Med. 2010. PMID: 20660382 Free article.

2

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. De Giorgi U, et al. J Clin Oncol. 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451443

3

Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer.

De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. De Giorgi U, et al. Clin Breast Cancer. 2012 Aug;12(4):264-9. doi: 10.1016/j.clbc.2012.04.004. Epub 2012 May 15. Clin Breast Cancer. 2012. PMID: 22591634

4

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. De Giorgi U, et al. Ann Oncol. 2010 Jan;21(1):33-9. doi: 10.1093/annonc/mdp262. Epub 2009 Jul 14. Ann Oncol. 2010. PMID: 19602564 Free article.

5

Prospective Study of Serial ¹⁸F-FDG PET and ¹⁸F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.

Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM. Peterson LM, et al. J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10. J Nucl Med. 2018. PMID: 29748233 Free PMC article.

6

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M. Haug AR, et al. J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331219 Free article.

7

Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV_max in [¹⁸F]fluoride and [¹⁸F]FDG PET?

Azad GK, Cousin F, Siddique M, Taylor B, Goh V, Cook GJR. Azad GK, et al. Mol Imaging Biol. 2019 Aug;21(4):781-789. doi: 10.1007/s11307-018-1262-3. Mol Imaging Biol. 2019. PMID: 30250989 Free PMC article. Clinical Trial.

8

18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.

Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G, DeCensi A. Piccardo A, et al. Nuklearmedizin. 2015;54(4):163-72. doi: 10.3413/Nukmed-0727-15-02. Epub 2015 Jul 13. Nuklearmedizin. 2015. PMID: 26165806

9

F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.

Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P. Gallowitsch HJ, et al. Invest Radiol. 2003 May;38(5):250-6. doi: 10.1097/01.RLI.0000063983.86229.f2. Invest Radiol. 2003. PMID: 12750613

10

18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.

Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H. Singnurkar A, et al. J Nucl Med. 2010 Dec;51(12):1833-40. doi: 10.2967/jnumed.110.076778. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078787 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

222 results

Results by year